- Home
- GLTO vs WKSP Comparison
GLTO vs WKSP Comparison
Compare GLTO & WKSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- WKSP
- Stock Information
- Founded
- GLTO 2011
- WKSP 2003
- Country
- GLTO Denmark
- WKSP United States
- Employees
- GLTO N/A
- WKSP N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- WKSP Auto Parts:O.E.M.
- Sector
- GLTO Health Care
- WKSP Consumer Discretionary
- Exchange
- GLTO Nasdaq
- WKSP Nasdaq
- Market Cap
- GLTO 12.0M
- WKSP 15.3M
- IPO Year
- GLTO 2020
- WKSP N/A
- Fundamental
- Price
- GLTO $6.94
- WKSP $0.55
- Analyst Decision
- GLTO Buy
- WKSP
- Analyst Count
- GLTO 1
- WKSP 0
- Target Price
- GLTO $10.00
- WKSP N/A
- AVG Volume (30 Days)
- GLTO 44.9K
- WKSP 377.6K
- Earning Date
- GLTO 11-04-2024
- WKSP 11-12-2024
- Dividend Yield
- GLTO N/A
- WKSP N/A
- EPS Growth
- GLTO N/A
- WKSP N/A
- EPS
- GLTO N/A
- WKSP N/A
- Revenue
- GLTO N/A
- WKSP $3,732,032.00
- Revenue This Year
- GLTO N/A
- WKSP $386.78
- Revenue Next Year
- GLTO N/A
- WKSP $294.52
- P/E Ratio
- GLTO N/A
- WKSP N/A
- Revenue Growth
- GLTO N/A
- WKSP 1190.52
- 52 Week Low
- GLTO $6.55
- WKSP $0.36
- 52 Week High
- GLTO $23.50
- WKSP $1.97
- Technical
- Relative Strength Index (RSI)
- GLTO 27.49
- WKSP 56.59
- Support Level
- GLTO $6.61
- WKSP $0.52
- Resistance Level
- GLTO $7.50
- WKSP $0.60
- Average True Range (ATR)
- GLTO 0.62
- WKSP 0.06
- MACD
- GLTO -0.31
- WKSP 0.01
- Stochastic Oscillator
- GLTO 6.67
- WKSP 73.05
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.